1581276-63-2

Usage

Uses

Used in Pharmaceutical Industry:
(3beta,4alpha,16beta,21beta,22alpha)-Olean-12-ene-3,16,21,22,23,28-hexol 21-[(2E)-2-methyl-2-butenoate] is used as a pharmaceutical compound for its anti-inflammatory properties, which can help in the treatment of various inflammatory conditions.
Used in Medicinal Industry:
(3beta,4alpha,16beta,21beta,22alpha)-Olean-12-ene-3,16,21,22,23,28-hexol 21-[(2E)-2-methyl-2-butenoate] is used as a medicinal compound for its anti-cancer properties, potentially contributing to the development of new cancer treatments by targeting and inhibiting the growth of cancer cells.
Used in Anti-diabetic Applications:
(3beta,4alpha,16beta,21beta,22alpha)-Olean-12-ene-3,16,21,22,23,28-hexol 21-[(2E)-2-methyl-2-butenoate] is used as an anti-diabetic agent, leveraging its ability to regulate blood sugar levels and improve insulin sensitivity, thus offering a potential therapeutic approach for the management of diabetes and related health conditions.

Downstream Products

• 13844-01-4 barringtogenol C 
• 20853-07-0 protoaescigenin 

Relevant academic research and scientific papers

New saponins from the seeds of Aesculus chinensis

Eight new acylated polyhydroxyoleanene triterpenoidal saponins, aesculiosides A-H (1-8), along with four known ones, have been isolated from the seeds of Aesculus chinensis. On the basis of extensive NMR studies, the structures of the new compounds were determined to be 21-O- tigloylprotoaescigenin 3-O-[β-D-glucopyranosyl-(1→2)][β-D-glucopyranosyl- (1→4)]-β-D-glucuronopyranosyl acid (1), 21-O-angeloylprotoaescigenin 3-O- [β-D-glucopyranosyl-(1←2)[[β-D-glucopyranosyl-(1→)]-β-D- glucuronopyranosyl acid (2), 21,22-O-ditigloylprotoaescigenin 3-O-[β-D- glucopyranosyl-(1→2)][[β-D-glucopyranosyl-(1→4)]-β-D-glucuronopyranosyl acid (3), 21-O-tigloyl-22-O-angeloylprotoaescigenin 3-O-[β-D-glucopyranosyl- (1→2)] [β-D-glucopyranosyl-(1→4)-β-D-glucuronopyranosyl acid (4), 21,22- O-ditigloylprotoaescigenin 3-O-[β-D-glucopyranosyl-(1→2)][β-Δ- glucopyranosyl(1→4)]-methyl β-D-glucuronopyranosate (5), 21-O-tigloyl-22-O- angeloylprotoaescigenin 3-O-[β-D-glucopyranosyl-(1→2)-l]β-D- glucopyranosyl-(1→4)]-methyl β-D-glucuronopyranosate (6), 21-O-tigloyl-28- O-acetylprotoaescigenin 3-O-[β-D-glucopyranosyl-(1→2)][[β-D- glucopyranosyl-(1→4)]-methyl β-D-glucuronopyranosate (7) and 21-O-angeloyl- 28-O-acetylprotoaescigenin 3-O-[β-D-glucopyranosyl-(1→2)][β-D- glucopyranosyl-(1→4)]-methyl β-D-glucuronopyranosate (8).

PREPARATION OF PROTOESCIGENIN FROM ESCIN

The invention relates to the process for preparation of protoescigenin from escin isolated from Aesculum hippocastanum. The process comprises the following steps: two-step hydrolysis under acidic and basic conditions, enrichment of the crude mixture of sapogenins with protoescigenin, isolation of the mixture of sapogenins in a solid form, purification of the obtained solid and isolation of high purity protoescigenin. The present invention also relates to protoescigenin monohydrate in a crystalline form and the preparation thereof. Protoescigenin is a polyhydroxyl aglycone, which can be used as the synthon in the chemical modifications of naturally occurring saponis.